<SEC-DOCUMENT>0000950170-24-037609.txt : 20240328
<SEC-HEADER>0000950170-24-037609.hdr.sgml : 20240328
<ACCEPTANCE-DATETIME>20240328071512
ACCESSION NUMBER:		0000950170-24-037609
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20240328
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240328
DATE AS OF CHANGE:		20240328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CalciMedica, Inc.
		CENTRAL INDEX KEY:			0001534133
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				452120079
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39538
		FILM NUMBER:		24793478

	BUSINESS ADDRESS:	
		STREET 1:		505 COAST BOULEVARD SOUTH
		STREET 2:		SUITE 307
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-952-5500

	MAIL ADDRESS:	
		STREET 1:		505 COAST BOULEVARD SOUTH
		STREET 2:		SUITE 307
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CalciMedica, Inc. /DE/
		DATE OF NAME CHANGE:	20230322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GRAYBUG VISION, INC.
		DATE OF NAME CHANGE:	20170717

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GRAYBUG, Inc.
		DATE OF NAME CHANGE:	20150303
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>calc-20240328.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-28T06:34:05.1715+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:calc="http://www.calcimedica.com/20240328" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_411f4a04-03c2-4b64-bcf9-4f849b601a7a" name="dei:AmendmentFlag" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc">false</ix:nonNumeric><ix:nonNumeric id="F_7214e033-9220-4c06-ae4d-260003cc7186" name="dei:EntityCentralIndexKey" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc">0001534133</ix:nonNumeric><ix:nonNumeric id="F_9532ff2f-282e-401d-ba73-2911d07a9498" name="dei:SecurityExchangeName" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc">NONE</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="calc-20240328.xsd"/></ix:references><ix:resources><xbrli:context id="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-28</xbrli:startDate><xbrli:endDate>2024-03-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e5de217d-dc01-40ea-bfd6-9bdd5b68ebf2" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_2ef4b769-b3ab-480d-946c-855c54ecb969" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 28, 2024</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a36af4fb-75db-4b57-8875-cf32e93421ae" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">CalciMedica, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
    <td style="width:18%;"/>
    <td style="width:41%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_227ccd57-a506-439c-a293-a1b32c9b0fb4" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_01d58a68-9c32-48fc-9ef5-b84c326bdb4a" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-39538</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_79cd8061-be92-40fd-b323-b9dfd2e5adad" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">45-2120079</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8a5cdd51-ae6d-4773-92fc-b747b5774c7c" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">505 Coast Boulevard South, Suite 307</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7dcbafbb-eb05-4918-8203-e800e9f7b4ba" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">La Jolla</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_f21879e6-2d3c-4c83-8356-572c62223419" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_76489bf4-93f8-4134-af8a-84e66e1c4860" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">92037</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_549fcfca-4e6f-4e89-8ae3-fa3471fe6ecf" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(858)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_0085832c-a645-4053-b5db-2e37dbdbad3e" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">952-5500</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e4591370-1aa8-4761-b2f6-3a2bdaf4fbcb" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Not Applicable</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf18265c-2063-4177-abaa-42b74ae6ede1" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d599932-46c6-4594-ad90-11cc9921e833" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74d3329d-ed4b-4679-8359-25d9ed51759d" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a6861cbc-b7e8-4eb0-bdb3-35ab17464cfc" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f3871531-4773-41aa-8b24-c4bb70eaf306" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_19632f3c-3da7-4c37-9880-38d37447ac5d" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CALC</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_9532ff2f-282e-401d-ba73-2911d07a9498;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Capital Market</span></span></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_05155e20-3b49-4bf9-8169-576576fe850f" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;"><ix:nonNumeric id="F_aa6552e3-b110-4205-9f88-fdd606df408f" contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02.             Results of Operations and Financial Condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 28, 2024, CalciMedica, Inc. issued a press release announcing its financial results for the year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this report.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01.            Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(d) Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.14%;"/>
    <td style="width:4.08%;"/>
    <td style="width:88.78%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="calc-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release dated March 28, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;"/>
    <td style="width:44%;"/>
    <td style="width:9%;"/>
    <td style="width:41%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CalciMedica, Inc.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 28, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">/s/ A. Rachel Leheny, Ph. D.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">A. Rachel Leheny, Ph. D.<br/>Chief Executive Officer<br/></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>calc-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">	</font><img src="img141153264_0.jpg" alt="img141153264_0.jpg" style="width:302px;height:59px;"></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">CalciMedica Reports 2023 Financial Results and Provides Clinical &amp; Corporate Updates</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Enrollment in CARPO, Phase 2b trial of Auxora&#153; in acute pancreatitis (AP), on track with topline data expected in 2Q 2024</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Auxora granted Investigational New Drug clearance by the FDA for Phase 2 trial in severe acute kidney injury (AKI); KOURAGE initiating in 2Q 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">CRSPA Phase 1/2 trial of Auxora in asparaginase-induced pancreatic toxicity (AIPT) expanded and progressing to Phase 2 following initial patient cohort results presented at ASH 2023</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Following a private placement financing in January, Company&#x2019;s cash position is expected to fund operations into 2H 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">LA JOLLA, CA, March 28, 2024</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x2013; CalciMedica Inc. (&#x201c;CalciMedica&#x201d;) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the year ended December 31, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;Over the course of 2023 and into this year, we have continued to build upon CalciMedica&#x2019;s clinical and financial strength, which has culminated in several recent achievements and has positioned us to execute on key milestones in 2024 including presenting topline data from our ongoing CARPO trial in acute pancreatitis in the second quarter,&#x201d; said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. &#x201c;Importantly, the support from leading life science investors in our recent private placement financing allows us to initiate KOURAGE, our Phase 2 trial of Auxora in severe AKI patients, and to continue to progress other key programs in our pipeline.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Recent Clinical and Preclinical Updates and Anticipated Milestones:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Phase 2b CARPO enrollment on track and topline data expected in 2Q: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Enrollment in CARPO, CalciMedica&#x2019;s randomized, double-blind, placebo-controlled Phase 2b trial of Auxora&#153; in AP patients, is expected to be complete and topline data from the trial to be announced in the second quarter of 2024. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">IND application for Auxora in AKI approved and Phase 2 KOURAGE trial initiation underway: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In February 2024, CalciMedica received clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for Auxora to be evaluated in a Phase 2 trial in AKI with associated acute hypoxemic respiratory failure (AHRF) which has been named </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">KOURAGE. CalciMedica expects to enroll the first patient in KOURAGE in the second quarter of 2024, with data expected in 2025.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Data from initial cohort of Phase 1/2 CRSPA study with St. Jude presented at ASH: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In December 2023, CalciMedica&#x2019;s collaborators at St. Jude Children&#x2019;s Research Hospital presented data from the initial cohort of the Phase 1/2 CRSPA study of Auxora in AIPT at the 65</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> Annual American Society of Hematology Meeting &amp; Exposition (ASH) in San Diego, CA. The data from the initial cohort compared to a historical matched control group showed fewer hospital and ICU days for treated patients. No patients in the CRSPA study required total parenteral nutrition, compared to 68.8% in the historical matched control group, who required 27 days of nutritional support on average. 27% of patients in the matched control group had greater than 30% pancreatic necrosis at 30 days compared to none of the Auxora-treated patients.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">CRSPA study expanded and continuing to enroll in Phase 2 portion of trial: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The CRSPA study has been expanded to additional sites, the dose used in the initial cohort has been established as the recommended Phase 2 dose and a target total trial enrollment has been set at 24. Data is expected in 2025.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Preclinical data presented at AKI &amp; CRRT: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In March 2024, CalciMedica presented data from preclinical studies of Auxora in AKI at the 29</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference (AKI &amp; CRRT) in San Diego, CA. The results of the studies indicate that Auxora has the ability to hasten the recovery of kidney function and improve survival in rat models of AKI through inhibiting the Orai1 channels on Th17 and endothelial cells.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">2023 Financial Results and Corporate Updates:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">As of December 31, 2023, CalciMedica had $11.2 million in cash, cash equivalents and short-term investments. </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In January 2024, CalciMedica completed a private placement of securities to new and existing investors for up to approximately $54 million in gross proceeds that includes initial upfront funding of $20.4 million and up to an additional approximately $33.1 million upon exercise of accompanying warrants. CalciMedica intends to use the upfront net proceeds from the private placement to fund the Company's ongoing Phase 2 clinical trials for Auxora in AP and AKI.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">As of the end of the first quarter of 2024, the Company expects its cash, cash equivalents and short-term investments to be approximately $25.5 million, which, based on its current operating plan, it expects to be sufficient to fund its operations into the second half of 2025.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Total operating expenses were $38.1 million for the year ended December 31, 2023, which included $16.2 million of one-time charges of which $10.5 million was non-cash, related to accelerated vesting of stock options and severance for employees of Graybug Vision, Inc. at the time of the reverse merger with Graybug. </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Net loss was $34.4 million, or $7.66 per share (basic and diluted) for the year ended December 31, 2023.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">                            </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Auxora&#153;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">CalciMedica's lead clinical compound, Auxora&#153;, is a potent and selective small molecule inhibitor of Orai1-containing CRAC channels that is being developed for use in patients with acute inflammatory and</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">immunologic illnesses. CRAC channels are found on many cell types, including immune system cells, endothelium cells and pancreatic acinar cells, where aberrant activation of these channels may play a key role in the pathobiology of acute and chronic inflammatory syndromes. Auxora is currently being evaluated in: (i) a Phase 2b trial for acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS), called CARPO, (ii) a Phase 2 trial in acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF), called KOURAGE, expected to initiate in the second quarter of 2024 and (iii) an investigator-sponsored Phase 1/2 trial, called CRSPA, being conducted in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) as a side effect of pediatric acute lymphoblastic leukemia treatment with asparaginase. There are currently no approved therapies to treat either AP, AKI or AIPT. In previous trials, patients responded well to Auxora regardless of severity or cause of disease. CalciMedica is also exploring the potential of Auxora treatment for other acute indications including acute respiratory distress syndrome.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About CARPO and AP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">CARPO is an international, randomized, double-blind, placebo-controlled, dose-ranging trial intended to establish Auxora&#x2019;s dose-response and efficacy in AP with accompanying SIRS. It is expected to enroll 216 patients. AP can be a life-threatening condition where the pancreas becomes inflamed, sometimes leading to pancreatic cell death or necrosis, systemic inflammation, organ failure and death. There are an estimated 275,000 hospitalizations for AP annually in the United States, of which approximately 40% present with SIRS, which can compromise the function of other tissues or organs, especially the lungs. Organ failure is responsible for much of the mortality seen in AP. There is currently no approved therapy for AP. Details of the CARPO trial are available on clinicaltrials.gov (</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">NCT04681066</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About KOURAGE and AKI</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">KOURAGE is a randomized, double-blind, placebo-controlled study that will evaluate 150 patients with Stage 2 and 3 AKI who have AHRF and are receiving oxygen by non-invasive mechanical ventilation, high flow nasal cannula or intermittent mandatory ventilation (IMV). AKI denotes a sudden reduction in kidney function, or the organ's ability to clean and filter the blood. AKI can result as a complication of other serious illnesses such as sepsis, respiratory infections and failure, acute pancreatitis, trauma, surgery and burns. There are approximately 3.7 million hospitalized with AKI in the United States each year with approximately 1.1 million of these patients advancing to Stage 2 and Stage 3 AKI, over half of whom have associated AHRF. The risk of serious morbidities and mortality is significant for advanced Stage 2 and Stage 3 AKI patients. There are currently no approved therapies for AKI.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About CRSPA and AIPT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">CRSPA is an investigator-sponsored Phase 1/2 trial being conducted in pediatric acute lymphoblastic leukemia (ALL) patients with AIPT, which is acute pancreatitis toxicity caused by the administration of asparaginase (such as Oncaspar and Rylaze). CalciMedica believes that the CRSPA trial has defined an optimal pediatric dose for Auxora in this setting and the trial is currently being expanded to additional sites and is expected to enroll 24 patients. Approximately 3,000 pediatric patients are treated for ALL in the United States each year and treatment with asparaginase triggers the development of AIPT in 7-10% of these patients, with approximately half developing pancreatic necrosis and/or pseudocysts. There are currently no approved therapies for AIPT. Details of the CRSPA trial are available on clinicaltrials.gov (</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">NCT04195347</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">       </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About CalciMedica</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora&#153;, a proprietary, intravenous-formulated CRAC channel inhibitor, has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica is currently conducting a Phase 2b trial (called CARPO &#x2013; </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">NCT04681066</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">) for AP with SIRS, with topline data expected in the second quarter of 2024, as well as supporting the ongoing Phase 1/2 AIPT study (called CRSPA &#x2013; </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">NCT04195347</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">), with data expected in 2025. CalciMedica plans to initiate its Phase 2 study (called KOURAGE) in AKI with associated AHRF in the second quarter of 2024 with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.calcimedica.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This communication contains forward-looking statements which include, but are not limited to, statements regarding CalciMedica&#x2019;s expected cash, cash equivalents and short-term investments as of the end of the first quarter of 2024; CalciMedica&#x2019;s expected use of proceeds from the private placement; CalciMedica's expected cash runway; CalciMedica's business strategy; CalciMedica's planned and ongoing clinical trials and the timing, design, expected patient enrollment thereof and the expected timing for the release of data from those trials, including its planned Phase 2 KOURAGE trial of Auxora in AKI with associated AHRF, its ongoing Phase 2b CARPO trial of Auxora for AP with accompanying SIRS and its ongoing Phase 1/2 CRSPA trial of Auxora in pediatric patients with AIPT; the potential benefits of Auxora for the treatment of AKI, AP and AIPT; the estimated patient populations in the United States for AKI, AIPT and AP; the potential of Auxora for the treatment of other acute indications including acute respiratory distress syndrome; and the potential of CalciMedica's proprietary technology to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. CalciMedica's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the impact of fluctuations in global financial markets on CalciMedica's business and the actions it may take in response thereto; CalciMedica's ability to execute its plans and strategies; the ability to obtain and maintain regulatory approval for Auxora; results from clinical trials or preclinical studies may not be indicative of results that may be observed in the future; potential safety and other complications from Auxora; the scope, progress and expansion of developing and commercializing Auxora; the size and growth of the market therefor and the rate and degree of market acceptance thereof; economic, business, competitive, and/or regulatory factors affecting the business of CalciMedica generally; CalciMedica's ability to protect its intellectual property position; and the impact of government laws and regulations. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption &#34;Risk Factors&#34; in CalciMedica's Annual Report on Form 10-K for the year ended December 31, 2023 being filed with the Securities and Exchange Commission (SEC) later today and elsewhere in CalciMedica's subsequent reports</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at </font><font style="color:#0563c1;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.sec.gov</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. These documents can be accessed on CalciMedica's web page at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ir.calcimedica.com/financials-filings/sec-filings</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. The forward-looking statements contained herein are made as of the date hereof, and CalciMedica undertakes no obligation to update them after this date, except as required by law.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">CalciMedica Contact:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Investors and Media</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Argot Partners</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Sarah Sutton/Kevin Murphy</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">calcimedica@argotpartners.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="range_a1_e43"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">(212) 600-1902</font><font id="range_a1_e39"></font><font id="range_a1_i14"></font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CALCIMEDICA, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_balance_sheets"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Balance Sheets</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except par value and share amounts)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.353%;"></td>
    <td style="width:1.02%;"></td>
    <td style="width:1.02%;"></td>
    <td style="width:13.263%;"></td>
    <td style="width:1.02%;"></td>
    <td style="width:1.02%;"></td>
    <td style="width:1.02%;"></td>
    <td style="width:13.263%;"></td>
    <td style="width:1.02%;"></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br>2023</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br>2022</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,530</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,327</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">149</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,708</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">367</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">254</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,605</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,730</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">167</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">147</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset, net</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">413</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,424</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,185</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,349</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and Stockholders&#x2019; Equity (Deficit)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,419</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,866</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical trial costs</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,141</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,143</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,468</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">572</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current liabilities</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">199</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,028</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,780</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term liabilities</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrant liability</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,645</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible promissory notes</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,157</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,028</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,582</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 9)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible preferred stock</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Series A convertible preferred stock, $0.001 par value; no shares and 25,751,716 authorized, issued and outstanding at December 31, 2023 and December 31, 2022, respectively</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,107</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Series B convertible preferred stock, $0.001 par value; no shares and 11,235,460 authorized at December 31, 2023 and December 31, 2022, respectively; no shares and 10,667,279 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,224</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Series C-1 convertible preferred stock, $0.001 par value; no shares and 8,016,886 shares authorized, issued and outstanding at December 31, 2023 and December 31, 2022, respectively</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,683</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Series C-2 convertible preferred stock, $0.001 par value; no shares and 16,291,526 authorized at December 31, 2023 and December 31, 2022, respectively; no shares and 13,504,959 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,563</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Series D convertible preferred stock, $0.001 par value; no shares and 88,875,077 authorized at December 31, 2023 and December 31, 2022, respectively; no shares and 26,880,040 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,494</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#x2019; equity (deficit)</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, $0.0001 par value; 10,000,000 shares and no shares authorized at December 31, 2023 and December 31, 2022, respectively; no shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $0.0001 par value; 500,000,000 and 5,694,626 shares authorized at December 31, 2023 and December 31, 2022, respectively; 5,754,505 and 84,165 issued and outstanding at December 31, 2023 and December 31, 2022, respectively</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154,218</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,402</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(146,064</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(111,707</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive income (loss)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#x2019; equity (deficit)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,157</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(71,304</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities, convertible preferred stock and stockholders&#x2019; equity (deficit)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,185</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,349</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CALCIMEDICA, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_statements_operations"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statemen</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ts of Operations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share amounts)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:68.76%;"></td>
    <td style="width:1.04%;"></td>
    <td style="width:1.04%;"></td>
    <td style="width:12.5%;"></td>
    <td style="width:1.04%;"></td>
    <td style="width:1.04%;"></td>
    <td style="width:1.04%;"></td>
    <td style="width:12.5%;"></td>
    <td style="width:1.04%;"></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,859</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,350</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,216</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,843</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,075</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,193</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(38,075</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(14,193</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of warrant liability</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,146</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,784</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of convertible promissory notes</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,022</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,745</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest on convertible promissory notes payable</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(110</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(132</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">660</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(28</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income (expense), net</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,718</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,369</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(34,357</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(7,824</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deemed distribution to convertible promissory note holders</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,318</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to common stockholders</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(34,357</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9,142</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share&#x2014;basic and diluted</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(7.66</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(111.16</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average number of shares outstanding used in<br>&#160;&#160;&#160;computing net loss per share&#x2014;basic and diluted</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,486,258</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,245</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img141153264_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img141153264_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "( K4# 2(  A$! Q$!_\0
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MWQD\#^ X?,U_Q5I6F#SC;E9;E2PD )*E1D@C:>H[5<(2J/E@KOR [*BO)?\
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MN'$8[#81I5II-[+J_D>K@LKQN8)RPM)R2W?1>KV/<J*;)(L,;.[*B*,LS'
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M@**** "BBB@ HHHH **** "O,_CA^T)X0^ >A?;?$5[NOIHV>STN#YKBY([
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MEHNE6NA:/8Z;8V\=I96<"6\%O$,)&BJ%50.P  %-U_7++PSH=_J^I3K;6%C
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M@>Z_\-0?#;_H8&_\ KC_ .(KXR^+6L:7K_Q$US4-&97TVXN&DA9(S&"#WVD
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ME*HJU.-2.S2?WGXGB*,L/6G1EO%M?<[!5/5M)LM>TNZT[4;6*]L+J-HI[>=
MR2(1@J0>HJY16R;3NCG/DCQ[_P $U_ASXD>>?0-0U/PO<22AQ&K"YMXUQRJH
MV&]\ES6M\-O^">/PQ\#W-E>ZH+WQ7?VXRPOW"6KONR&\I1GC &UF8'G(-?4-
M%>H\TQKA[-U7;\?OW*YF5]/T^UTFQ@L[&VAL[.!!'%;V\8CCC4=%51P /058
MHHKRMR0HHHH **** /RH_P""@WP?G^'_ ,9)_$4(DDTKQ-NO$E?)"SY_>IG
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MV+Q!-,T3Q2% C\@'((5.,<$'UKTJF&J8O)Z=+#ZMJ/\ P?Q*M>.A^N5?#/\
MP5&\'-=^%?!WBA99#]BNI;!X5CRH650^\MGCF(#&.=U,^&'_  4>U;XA?$CP
MSX9?P39V<.KZC;V+7"WSLT8DD5"P&P9(SG%?7/Q<^&>F_%[X>ZSX4U4?Z-?P
ME4D&<Q2#F.08ZE6 ./:ODJ-.MDV,I5,0K?<]-F9ZQ>I^:W_!//XFVG@/XX#3
M+[8EOXAMS8+,V<I)N#(./4C'/K7ZLU^'GQ6^%'B7X'^-[C0==MWM;RW;S(+J
M+/ESIGY9(V[@X^H/!Y%?0OPG_P""D'C3P5I=KI?B;3;?Q9;0E$6\DD,5T(P?
MFRP!#MCH2!TY)KZ3.,JGCY1Q6%:=UWW[-%RC?5'Z?5A^-O&VB_#OPO?^(?$-
M_'IVDV,?F33R?HJCJS$\!1R20!7QGXD_X*DZ)'IN=!\%WTU_O'RZC<(D6WN<
MIDYZ=J^2OCY^T_XR_:%O;<:Y+%9Z3:NSVNEV0*PH23AFR<NX4A=Q[#@#)SXN
M$X?Q5::]NN6/7:_R)4'U/U^\">/-"^)7A:Q\1>'-0CU+2;Q=T<T?4'NK \JP
M/!4\@U\X_P#!23Q3+H?[/L>FQPI(FM:K!:R.QP8P@:<$>IS$!]":\Z_X)M_#
M+X@: VJ>)+VYFTGP3>H8TTNZ0YO9P0!,BG[@7!7?_%TYQD<[_P %2?%5O=>*
MO!/AZ&XF^TV=I<7ES;X(CVRLBQ-Z$_NI1[?C5X7 PHYO&C3ES*+OZ6UL_-/^
MN@)>]8\A_8(\+0>)OVDO#QNK62Y@T])K[<N<1R1H3&S$=M^WKWQ7ZV7MY'I]
MG/=3$B&&-I'(&2%49/'T%?GQ_P $M?"\TGB#QKXC$Z""&UBL#!@[BTC[PWI@
M"(C\:^U?C9K;>'_A;XBNX[I;2?[,8XI"1G<W&!GN037'Q3BE#$3D]J<?TN=6
M'H/%8FG0CO)I?>['Y^>)M0_MKQ-J-WYDDHN+EW#R$EB"QZYK]&OA[HJ^'? ^
MA::DQG6WLXT$A7;N^4'..W6OSW^&FCS>(OB!H-E%"MQ)+>1DQR8VL P+9SVP
M#7Z3JJQJ%50JJ,!0, "OQOA.FY.MB)>2_5_H?K?B)74(X;!QV5W^27ZCJ***
M_1#\6"L7QIK$/A_PEJ^HSR-#%;VLCF1 2R_*<$8]\5M5Y3^TYK<NB_!_5S!)
M&DER4MR'QEE9OF ]\5QXRM]7PU2K_*F_P/3RS#?7,=1P_P#-**^]GPOI=N^N
M^(K:!YFWW5RJF9\L<LW4^O6OTTTRS_LW3;2TW^9Y$*1;L8SM4#/Z5^?O[/\
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MP#HL@';HP''/%?7-?-XK"U<'4=*LK/\ /T,FK!1117((**** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>calc-20240328.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-28T06:34:05.6668+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.calcimedica.com/20240328" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:calc="http://www.calcimedica.com/20240328" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="calc-20240328.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672136322944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 28,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CalciMedica, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001534133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-2120079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">505 Coast Boulevard South, Suite 307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La Jolla<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">952-5500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">Not Applicable<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CALC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NONE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .0Y?%@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #D.7Q8D@^\+.\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O:9U(J'+BV-/"H(#Q;>0W+9@DX;DI-VW-ZU;A^@'\#%W__SN
M=W"M#D+W$9]C'S"2Q70SNLXGH<.:'8F" $CZB$ZE,B=\;N[[Z!3E9SQ 4/I#
M'1#JJKH#AZ2,(@43L @+D<G6:*$C*NKC&6_T@@^?L9MA1@-VZ-!3 EYR8'*:
M&$YCU\(5,,$(HTO?!30+<:[^B9T[P,[),=DE-0Q#.31S+N_ X>WI\65>M[ ^
MD?(:\Z]D!9T"KMEE\FOSL-EMF:RK^K:HFJ*^WW$N^$I4J_?)]8??5=CUQN[M
M/S:^",H6?MV%_ )02P,$%     @ Y#E\6)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M%/:!O0&N+Z4T^X']5%!]Z1G_"U!+ P04    " #D.7Q8GZ ;\+$"  #B#
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M#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ Y#E\6 =!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" #D.7Q8D@^\+.\    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " #D.7Q8F5R<(Q &  "<)P  $P
M    @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .0Y?%A+
MN09SI 0  /41   8              " @0X(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " #D.7Q8GZ ;\+$"  #B#   #0
M    @ 'H#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .0Y?%B7BKL<P
M !,"   +              "  <0/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M .0Y?%@ZJJ+G0 $  #P"   /              "  :T0  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " #D.7Q8)!Z;HJT   #X 0  &@
M@ $:$@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #D
M.7Q899!YDAD!  #/ P  $P              @ '_$@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"  !)%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="calc-20240328.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName -  calc-20240328.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="calc-20240328.htm">calc-20240328.htm</File>
    <File>calc-20240328.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "calc-20240328.htm": {
   "nsprefix": "calc",
   "nsuri": "http://www.calcimedica.com/20240328",
   "dts": {
    "inline": {
     "local": [
      "calc-20240328.htm"
     ]
    },
    "schema": {
     "local": [
      "calc-20240328.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20240328.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20240328.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.calcimedica.com/20240328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-24-037609-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-037609-xbrl.zip
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MZGO#Z/[Y#C>$ZK]>7I^C612\0-L[L]4WMQDW=)>!>M)T4-^<X"!D#O8#QNS
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MN<;;#Q_617]8#Q(V_/+#8;V3=Z,O_P]02P,$%     @ Y3E\6!Q4BDC7"
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M) 0#/AI@</7SE_HCVZD0D"# !"%H UIR[LF60E8@!@P?&O6KB V6[=AS'!
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M[BDKUG!W678+EP@0F\]0\(7MP>6/6N;;^<,+B>_P#ZX$_Z/ Z?]02P,$%
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MX^$KQOUD\1<Y">LGMUL.\%_&:MTCS8N;0"/2\$.9RGX*N:SF+(*P*JSP)!3
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M Q7EW)$Q!Q!S+*Y$)#*>^"Z]4$S@XS_3: ),\>OY_@G[]<OO%Z?_^ "? JO
MF\+A B8@DGNI)'=V<?GU-*,;^ZTS+U:U0(7%1!Q@@FO0J4E=H,U"OKH@26^D
M*Q.DJ/.OW_91F((>AVM0FX\C-8Q$'"-=):H@T %(=G5MB WISH<')A)%O:M&
M8"&P*+,(  6QT-S $W9Z^8NV'$@V$Z-L>HL_%A3+@2CE%1JB8Q]>K@V4@3%E
MC?#\)P]3'DTL,%D#8(7)CS_<."W[Z"1F+H]';*QBB1*=@652&![ &X,4^$6-
M1:3E?0Q/@@\=3?'=K>/^9='7GRGHU<%D P2V#.1/I^R?7SY].@4B@7^_\<@=
M,>?0>K+I^1P.'-N0O%U.'L@_8-V7/<GST&VR/?.5>U+ZQGSDG>RSO<\\]OA?
MQX#B3V?@ ' PG(Q+"2S/AV ]234>\2B 5:>)=C5=P[&@G]PT!K8$+O7 A/+5
M&'D[5/ K,#&\*PU 18$9!BJ1NXD6!U[QS=[9Q>G9/G-'/ P%VF$Z*(8L#\8:
M8$8"G:*Y9LPR5)/N*%*P,KATX/,@X(D""PV_D$&0AH#J(7[I^R&H4A%;("X\
M/H$5H#<-+QX4GG2N-_'Q:!E.P%)D0JOC]P*$55]$K&UK.FLWM\]Q)%:>@U7<
MDR]@]NO]=U4:@<4%!IT.N6B20KV2C$#[('%8[%JP$;_"2T,P_U.CC/JI]#V6
MCH%F;_&6UF1Y< :?."6_.(E$.$Q&\-21!)$&YAYS4Q^6RS/W6GLDFE!1T0 +
MC"1\@DK4A'_PCEQ#PAUIC*L1-T*S"JSF.W@P@!=PC.#[6/LJ(#+AI^NGF+O(
M+49C<)9\_$&D @;8@(<,%7ZK(PI35VE!W$!JAH4E VH\]A<H==",5BY@6,RE
MQRX  N#Q3V(DP@G&)YKOFR#4 :H!^Z"7+0&W7P8#Z<*6P#Z4T-ED^7Z=YRD8
M'YZAWYF.\1.S:I S&C1?#N ;%^QD</VD]@Y5I)>)<&48766<<+1AX@RIF<<G
M<A?0TD^9=2%G'(',F02_,;?601+AGL'#<N+!WW.;GRD4=WK']$<\*-8ZEF.!
M6]/,D;E]+B51],QFQ(6AS[.RY/@*1)O_G85U]>>G0$VN'&NA\5O![<>U"_F6
MLZ^E/&.[V6ZWWYQX,@8NGQP/?'$S"W2V_?GC]15H]$3)B0:O 8 $\7$?>!W9
M\!8BIHO,7G4'9IZFXI8G8MO-3N?@R#ZR.UV[U6L?'4R!EB&NO*%A7P%NIA,=
MIT!M":?F)7:K-?_8*O%-$?(V"DM,P^)%1-L(X:4![>-M6_ +0_D+[8H(0%$!
MO-&SF*?2OB\:?0 +_M+ZK*_T4_%I -S=R8#3KR55->=O]X4V]WV1V>"WK054
MQ.;1YG(PYU4:N@:MMRV#S,KJ-*?A(*R/V%J5!(DP$F'5$&'GG]\S/@;V<G5L
M2WNG4[L2#4KX-@+OV@2-<QLTSTWD-KK)4,#]*3BTT36 NFW!=AZRCZ(?8;A/
ML_Z,5-,6N42@I@D;$!$2/)VEJ9T]0-7^#*ZR%,_OS<LF^ZB4P9"^]M2#94EP
MN<R%>Q_?G^Z746N$EKCB?II[7_QVB@BQKS.B/(Z5*_65QA<:3<;J1@32Q:C"
M6$8F*C'@TD_!#=@[_>7BXW[)S^L+$;*0!W#_$OE7(EM-WIX$#.':CV'+TB"<
ME099,5K!T<VN-'Q5JD%;R#4B]$[ZZ@;W%XO9^BH":H''Z#*:Y[09(US7T^3*
M?/75ZJ*C<HU5Y:SA^?JIIZF2JH%W\*"-N@U.P12C*'_CF _!VHD$_][@ [ G
MCKD/,BY^4"$F:=M;VO9*QK(O?9E,CD?2\T3X</V[";V[!FV4Z<OFC!(R)J\)
MHVDS7*N3@8SBI$BZ@AJ8U@&LL&PMHRENNQ@MI]LDHY>,7C)ZIX3QOO C\QJ'
MK+8!F&E:<&$*,.(D]2:&N2Z3)OMGZHE;I0]5,':+'!)F$Y:X\+ BG_>5-A=C
M7'L!T=E(^EXDPNFU%P"BSGW^HL#"3+ .I(!ZU@^_C4/\=#$>9Z+66)2"J\#+
M>]U'HO!*1#I!F+%2G(Y%5#8&FNUY>^!!F$U&6]Y:=AJ&*6#W-(#+7!ZR2W %
M1*)1^8O ?*2OAA/VFQ ZL6(J<C_<%*4,>T"?^XCM2[CWO11#A8GM)OLVFH^G
MS.VC3KA&)B##V4AB1D-'@^&=[@A=)Q/N8<-(I:!*1NH:\YWB&FAPE-,,>D3G
M9[_#FR99YA-3.+I*R<1^FNRS*O[(55R98B+Q5RK-,C01PI*P"@)^#5/PE!!&
M:V:MO</FX9O\27<M&[-A:OH.Y\"L%'!;/!US9UG*!]#),4<V%$VX] U>-K_T
MQ<@9<0]^0\@Q]P<;T6Z]*1=JA<*-8,,T3[9;9@UEF$(5BIRQ#/\T;B&2E#PI
M>5+R\_631HC,%#YF"=&L[C&SO(%]\_@+LCI*3N0W=!VWKMV_S8G$(J13@(4B
MVO,*<05KB4VRVE, DJZ7R>33G)"?/@JVO>_+&&47?(:71N!H!(&I4,EQHY^'
M2.0,R&0HDDPLFYA5*0%2/#B&:T"J8>Q=FUWE4#_Y)R2Z2'0MR"N6<N_:1IMU
M.'X]SQNO+BZ^;5TZ@>^1%4G>BK(O\AC&)=A0G&'%W:Q7@#D'XQ0X1^04+'8*
MSM$&#O,<Q:E."OQJFDC.31,)"NDSH^E4BNY<J+OYIK5'WW3!XP0O&HA(%R[M
MS9+6,K<AKV3,#-)\%V6(FPX+ 0LWR3=TE"D3;N)\J*G@(P"C4#&P5]J9R7I@
M!FFH$P]9C:7./8$!'EW)*Y,5 >^5!<H3OJ$;6'$R B-[."JJ.5&QP\._1%S:
M>:EGC,;[MY%]H)\+2@TKH'RM"87OD_6LZEO]M*+C]59GZR;KG"I3#5=%D^19
M"GI?CE6R!E(XU?+U5FGZK(;'P,9KVVXZ6/GKZ]:94/?26*:C!@,K(+>+&N(8
MO8X&Z*X@JY(-3!#H[K0T45YM*.^\:-1:8%/FA6'>PFXOH-A8N"E&[H1.K(6
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MC)09YXA.EFFBB$0VB42GS&XF0Z&GBF"6#5PF'F,8-!#H NL8ZA4:XWZF5$9
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M85-B"DKNT-GEL@Q]??D!K9/-\.Y35#I.Y]'#".;F"Y'<JC[L3]CWUSLL@)X
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MV4=D0.Y*"'+72ZT^J3AF@T@%3"WJPR.A34*;A/;=4]5>GC58E0--B$5(@-1
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M;&,M,C R-# S,C@N>'-D4$L! A0#%     @ Y3E\6(2:TS=!*0  S,X"  \
M             ( !H!P  &-A;&,M97@Y.5\Q+FAT;5!+!08      P # +L
(   .1@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>calc-20240328_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="calc-20240328.xsd" xlink:type="simple"/>
    <context id="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
        </entity>
        <period>
            <startDate>2024-03-28</startDate>
            <endDate>2024-03-28</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_411f4a04-03c2-4b64-bcf9-4f849b601a7a">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_7214e033-9220-4c06-ae4d-260003cc7186">0001534133</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_9532ff2f-282e-401d-ba73-2911d07a9498">NONE</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_e5de217d-dc01-40ea-bfd6-9bdd5b68ebf2">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_2ef4b769-b3ab-480d-946c-855c54ecb969">2024-03-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_a36af4fb-75db-4b57-8875-cf32e93421ae">CalciMedica, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_227ccd57-a506-439c-a293-a1b32c9b0fb4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_01d58a68-9c32-48fc-9ef5-b84c326bdb4a">001-39538</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_79cd8061-be92-40fd-b323-b9dfd2e5adad">45-2120079</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_8a5cdd51-ae6d-4773-92fc-b747b5774c7c">505 Coast Boulevard South, Suite 307</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_7dcbafbb-eb05-4918-8203-e800e9f7b4ba">La Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_f21879e6-2d3c-4c83-8356-572c62223419">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_76489bf4-93f8-4134-af8a-84e66e1c4860">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_549fcfca-4e6f-4e89-8ae3-fa3471fe6ecf">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_0085832c-a645-4053-b5db-2e37dbdbad3e">952-5500</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_e4591370-1aa8-4761-b2f6-3a2bdaf4fbcb">Not Applicable</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_cf18265c-2063-4177-abaa-42b74ae6ede1">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_0d599932-46c6-4594-ad90-11cc9921e833">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_74d3329d-ed4b-4679-8359-25d9ed51759d">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_a6861cbc-b7e8-4eb0-bdb3-35ab17464cfc">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_f3871531-4773-41aa-8b24-c4bb70eaf306">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_19632f3c-3da7-4c37-9880-38d37447ac5d">CALC</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_05155e20-3b49-4bf9-8169-576576fe850f">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_6ad8604e-dc7a-43ba-89e7-5db2aa8479dc"
      id="F_aa6552e3-b110-4205-9f88-fdd606df408f">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
